Network Meta-Analysis Reveals Optimal Chinese Herbal Preparations for Gastric Cancer Treatment

A landmark network meta-analysis has provided the most comprehensive evidence to date on the effectiveness of commercial Chinese polyherbal preparations (CCPPs) as adjuvant treatments for gastric cancer, analyzing data from 189 randomized controlled trials involving 15,320 participants across China.

The study, published in Frontiers in Pharmacology, evaluated 27 different CCPPs combined with oxaliplatin-based chemotherapy regimens, establishing a clear hierarchy of effectiveness for various therapeutic outcomes in gastric cancer patients.

Key Therapeutic Findings

The analysis revealed that no single CCPP was universally superior across all treatment outcomes, but several preparations demonstrated distinct advantages for specific therapeutic goals. Compound Mylabris preparations emerged as the most effective for disease control rate (DCR), showing a 51% improvement compared to oxaliplatin-based chemotherapy alone (RR 1.51, 95% CI 1.13-2.03).

Kangai Injection demonstrated the most robust overall profile, providing broad intermediate efficacy across multiple outcomes including a 40% improvement in objective response rate (RR 1.40, 95% CI 1.28-1.77) and a 46% improvement in quality of life (RR 1.46, 95% CI 1.11-1.94), while also significantly reducing adverse events.

For patients prioritizing quality of life improvements, several preparations showed moderate to high certainty evidence of benefit. Aidi Injection increased quality of life improvement rates by 30% (RR 1.30, 95% CI 1.13-1.50), while Ya Dan Zi Oil Emulsion Injection and Lentinan also demonstrated significant benefits with 26% and 27% improvements respectively.

Immune Function Enhancement

The analysis revealed substantial evidence for immune system benefits from various CCPPs. Shenmai Injection showed significant improvements in both CD3+ T cells (MD 10.03, 95% CI 1.69-18.37) and CD4+ T cells (MD 8.33, 95% CI 0.64-16.02). Kangai Injection enhanced CD3+ levels by 11.65 points (95% CI 6.81-16.50) and improved the CD4+/CD8+ ratio by 0.25 (95% CI 0.02-0.47).

Ginseng Polysaccharide Injection and Huachansu preparations also demonstrated significant immune-enhancing effects, with the latter showing improvements in both CD3+ levels and natural killer cell activity.

Safety Profile and Adverse Events

A critical finding was the superior safety profile of several CCPPs. Kangai Injection reduced myelosuppression events by 48% (RR 0.52, 95% CI 0.39-0.69) and gastrointestinal events by 35% (RR 0.65, 95% CI 0.54-0.79). Lentinan and Yangzheng Xiaoji Capsules showed similar protective effects against both myelosuppression and gastrointestinal toxicity.

The study found that Aidi Injection, Astragalus Polysaccharides, Compound Kushen Injection, and Huachansu preparations all demonstrated significant reductions in chemotherapy-related adverse events when combined with oxaliplatin-based regimens.

Clinical Context and Significance

Gastric cancer remains a major global health challenge, ranking fifth in incidence with 1.089 million cases and third in cancer-related mortality with 768,000 deaths globally. China accounts for 48.6% of global gastric cancer-related mortality, making effective adjuvant treatments particularly crucial.

The research addressed a significant gap in comparative effectiveness data for traditional Chinese medicine preparations. Previous studies had evaluated individual CCPPs, but this network meta-analysis provided the first comprehensive comparison of all available options using rigorous GRADE methodology to assess evidence certainty.

Methodological Rigor

The study followed PRISMA 2020 guidelines and employed a frequentist network meta-analysis framework using random-effects models. Evidence certainty was assessed using the GRADE approach, with treatments categorized into efficacy-based clusters ranging from most to least effective based on both statistical significance and clinical relevance.

The analysis included studies spanning treatment durations from 10 to 180 days, with participants having a mean age of 55.39 years and 62.50% being male. The most frequently studied preparations were Aidi Injection, Compound Kushen Injection, and Shenqi Fuzheng Injection.

Clinical Implications

The findings have direct implications for clinical practice and guideline development. The research provides clinicians with evidence-based hierarchies for selecting CCPPs based on specific therapeutic goals, whether prioritizing tumor response, quality of life improvement, immune function enhancement, or adverse event reduction.

The study's authors noted that the choice of adjuvant CCPP should be individualized based on specific therapeutic priorities, balancing efficacy and safety considerations. This personalized approach represents a significant advancement in integrative oncology care for gastric cancer patients.

Future Research Directions

The researchers identified several areas for future investigation, including the need for larger, multi-center, double-blind randomized controlled trials with standardized methodologies. They also emphasized the importance of real-world studies based on large-scale healthcare databases to assess long-term safety and efficacy in diverse patient populations.

The study's comprehensive approach to evaluating traditional Chinese medicine preparations provides a model for future research in integrative oncology, demonstrating how rigorous systematic review methodology can be applied to traditional medicine interventions to generate clinically relevant evidence.